Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$118.33

3.02 (2.62%)

07:21
02/27/18
02/27
07:21
02/27/18
07:21

GW Pharmaceuticals receives orphan drug designation for cannabidiol treatment

GW Pharmaceuticals announced that the European Medicines Agency has granted orphan drug designation for cannabidiol for the treatment of tuberous sclerosis. GW is currently recruiting a Phase 3 clinical trial of Epidiolex as an adjunctive therapy for the treatment of seizures associated with TS, with data expected in the second half of 2018. Subject to positive results, GW expects to submit regulatory applications in 2019 for Epidiolex in TS in both the U.S. and Europe. TS is multisystem, genetic disease that causes benign tumors to grow in the brain and on other vital organs. TS can be life threatening in patients with severe symptoms, including drug resistant seizures and kidney failure. Up to 80 to 90% of individuals with TS will develop epilepsy during their lifetime, with onset typically in childhood. The seizures are often severe, and up to two-thirds of TS patients do not respond adequately to available medical therapies. There are significant co-morbidities associated with TS including cognitive impairment, autism spectrum disorders, developmental delay with severe learning disability and neurobehavioral disorders in individuals with TS. The EMA orphan designation is a status assigned to a medicine intended for use against a rare condition and allows a pharmaceutical company to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life-threatening or a chronically debilitating rare disease. These incentives can include reduced fees and protection from competition once the medicine is placed on the market. GW has already received orphan drug designation from the FDA for CBD in the treatment of TS.

  • 27

    Jun

GWPH GW Pharmaceuticals
$118.33

3.02 (2.62%)

12/29/17
LEER
12/29/17
NO CHANGE
LEER
Outperform
GW filing acceptance, FDA panel in line with expectations, says Leerink
Leerink analyst Paul Matteis said the FDA accepting the Epidiolex new drug application and granting of priority review were in line with expectations given the three positive late-stage studies and the unmet need for the two rare orphan epilepsies. The analyst thinks an Advisory Committee was likely given that Epidiolex is a plant-derived cannabinoid drug seeking a primarily pediatric indication. Matteis yesterday reiterated an Overweight rating on shares of GW Pharmaceuticals.
01/23/18
LEER
01/23/18
NO CHANGE
Target $153
LEER
Outperform
Leerink cautiously optimistic ahead of GW Pharmaceuticals CBDV Phase 2 data
Leerink analyst Paul Matteis reiterates an Outperform rating on GW Pharmaceuticals, while lowering his price target on the shares to $153 from $154, ahead of CBDV Phase II data in partial-onset seizures in Q1. While he acknowledges that is difficult to garner conviction in the Phase 2, his analysis of pre-clinical results - compared side-by-side to cannabidiol - instills him with "cautious optimism" on the program, while he believes that the little credit priced into the stock for CBDV sets up an upside skewed risk/reward on the upcoming data readout this quarter.
02/06/18
CANT
02/06/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals price target lowered to $192 from $208 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for GW Pharmaceuticals to $192 following the company's Q1 financial results and recent equity raise. The analyst, however, believes the shares remain "significantly undervalued," based on his assessment of Epidiolex's opportunity in treating orphan pediatric epileptic conditions. He reiterates an Overweight rating on GW.
02/22/18
CANT
02/22/18
NO CHANGE
Target $192
CANT
Overweight
GW Pharmaceuticals shares could recover quickly, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals shares could recover quickly from the selloff on the negative results with GWP42006 in adult patients with focal seizures. The analyst highlights the announcement of an advisory committee hearing for Epidiolex on April 18. The "clear near-term focus" is the successful commercialization of Epidiolex for pediatric pharmacoresistant seizures upon potential approval in the second half of 2018, Piros tells investors in a research note. He keeps an Overweight rating on GW shares with a $192 price target.

TODAY'S FREE FLY STORIES

GE

General Electric

$10.05

-0.055 (-0.54%)

15:00
02/21/19
02/21
15:00
02/21/19
15:00
Options
100K GE Mar 8th 9 puts bought for 5c with shares flat at $10.10 »

100K GE Mar 8th 9 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$43.81

-1.35 (-2.99%)

14:59
02/21/19
02/21
14:59
02/21/19
14:59
Periodicals
Anadarko says 4 injured in attack at Mozambique LNG project, Bloomberg reports »

Anadarko Petroleum said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

  • 22

    May

ALB

Albemarle

$88.17

5.35 (6.46%)

14:54
02/21/19
02/21
14:54
02/21/19
14:54
Recommendations
Albemarle analyst commentary  »

Albemarle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 27

    Feb

PBR

Petrobras

$16.70

-0.01 (-0.06%)

14:53
02/21/19
02/21
14:53
02/21/19
14:53
Periodicals
Brazil minister says Petrobras TOR auction may occur in late 2019, Reuters says »

Brazil's Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TI

Telecom Italia

$5.92

-0.12 (-1.99%)

14:51
02/21/19
02/21
14:51
02/21/19
14:51
Hot Stocks
Telecom Italia sees organic group EBITDA to decrease low single digit in 2019 »

TIM's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:50
02/21/19
02/21
14:50
02/21/19
14:50
Hot Stocks
Breaking Hot Stocks news story on Tim Participacoes »

TIM Participacoes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$51.60

-2.03 (-3.79%)

14:49
02/21/19
02/21
14:49
02/21/19
14:49
Options
Roku options imply 18.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

, QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

14:47
02/21/19
02/21
14:47
02/21/19
14:47
Conference/Events
Quad/Graphics to host special shareholder meeting »

Special Shareholder…

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

FB

Facebook

$160.21

-2.4 (-1.48%)

14:46
02/21/19
02/21
14:46
02/21/19
14:46
Periodicals
Kids advocacy groups urge FTC to probe Facebook over game purchases, Adweek says »

Childrens' advocacy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

, LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

14:41
02/21/19
02/21
14:41
02/21/19
14:41
Conference/Events
LSC Communications to host special shareholder meeting »

Special Shareholder…

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GIL

Gildan Activewear

$34.04

-0.13 (-0.38%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Downgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Earnings
Tim Participacoes releases guidance for 2019-2021 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$32.55

-1.24 (-3.67%)

14:35
02/21/19
02/21
14:35
02/21/19
14:35
Options
Ctrip.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 04

    Mar

  • 20

    Mar

NAII

Natural Alternatives International

$11.15

(0.00%)

14:34
02/21/19
02/21
14:34
02/21/19
14:34
Hot Stocks
Natural Alternatives International hires David Brook for sports nutrition unit »

Natural Alternatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

14:24
02/21/19
02/21
14:24
02/21/19
14:24
Hot Stocks
Nintendo of America president, COO Reggie Fils-Aime to retire »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.83

-0.21 (-1.40%)

14:23
02/21/19
02/21
14:23
02/21/19
14:23
Hot Stocks
Fiat Chrysler to propose EUR0.65 per share dividend »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.43

-0.32 (-0.73%)

14:20
02/21/19
02/21
14:20
02/21/19
14:20
Options
20K iShares Brazil Fund Mar 44 - 46 call spreads sold at 60c »

20K iShares Brazil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/21/19
02/21
14:17
02/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/21/19
02/21
14:16
02/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$34.55

-1.08 (-3.03%)

14:15
02/21/19
02/21
14:15
02/21/19
14:15
Options
Baozun put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$44.16

1.3 (3.03%)

14:11
02/21/19
02/21
14:11
02/21/19
14:11
Downgrade
Gentherm rating change  »

Craig-Hallum downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

PTC

PTC

$91.88

0.04 (0.04%)

14:08
02/21/19
02/21
14:08
02/21/19
14:08
Hot Stocks
New offering from PTC and ANSYS brings real-time simulation to design engineers »

PTC announced the release…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

HSC

Harsco

$24.48

2.54 (11.58%)

14:06
02/21/19
02/21
14:06
02/21/19
14:06
Recommendations
Harsco analyst commentary  »

Harsco has opportunity to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

THRM

Gentherm

$44.10

1.24 (2.89%)

14:06
02/21/19
02/21
14:06
02/21/19
14:06
Downgrade
Gentherm rating change  »

Gentherm downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.66

-0.76 (-0.27%)

14:04
02/21/19
02/21
14:04
02/21/19
14:04
Periodicals
CEO of container ship giant Maersk sees global trade war escalation, FT says »

Moller-Maersk CEO Soren…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.66

-0.76 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.